Representative before the EPO

Technology company logo thumb
no operation time available
1 office
Technology Company

Michael Stierwald has worked on the following 25 EPO patent applications which have been published in the last five years:

EP13741412

HETEROCYCLIC COMPOUNDS AND METHODS FOR THEIR USE

IPC classification:
A61K 31/4355, A61K 31/436, A61K 31/4365, A61K 31/437, A61K 31/4375, A61K 31/519, A61P 25/02, A61P 25/04, A61P 35/00, C07D 211/60, C07D 211/66, C07D 471/04, C07D 491/048, C07D 491/056, C07D 495/04
Applicant:
Novartis AG
Agent:
Philippe Becker, Cabinet Becker & Associés
Agent:
Multiple attorneys, Novartis Pharma AG
Status:
EXAMINATION IN PROGRESS
EP13741446

HETEROCYCLIC COMPOUNDS AND METHODS FOR THEIR USE

IPC classification:
A61K 31/496, A61K 31/4985, A61K 31/551, A61P 25/02, A61P 25/04, A61P 35/00, C07D 241/04, C07D 243/08, C07D 403/04, C07D 413/04, C07D 413/06, C07D 487/04
Applicant:
Novartis AG
Agent:
Philippe Becker, Cabinet Becker & Associés
Agent:
Multiple attorneys, Novartis Pharma AG
Status:
EXAMINATION IN PROGRESS
EP13706360

AQUEOUS PHARMACEUTICAL COMPOSITION WITH ENHANCED STABILITY

IPC classification:
A61K 9/00, A61K 9/08, A61K 47/02, A61K 47/36, A61K 47/48
Applicant:
Novartis AG
Applicant:
Alcon Research, Ltd
Agent:
Günter Keller, Lederer Keller Patentanwälte Partnerschaft mbB
Agent:
Michael Stierwald, Novartis Pharma AG
Status:
GRANT OF PATENT INTENDED
EP13723623

OPHTHALMIC COMPOSITIONS WITH IMPROVED DESSICATION PROTECTION AND RETENTION

IPC classification:
A61K 9/08, A61K 47/02, A61K 47/10, A61K 47/26, A61K 47/32, A61K 47/36
Applicant:
Novartis AG
Applicant:
Alcon Research, Ltd
Agent:
Oliver William Kingsbury, Elkington and Fife LLP
Agent:
Michael Stierwald, Novartis Pharma AG
Status:
GRANT OF PATENT INTENDED
EP13725348

AQUEOUS PHARMACEUTICAL COMPOSITION CONTAINING A BIOLOGIC THERAPEUTIC AGENT AND GUANIDINE OR A GUANIDINE DERIVATIVE AND AN INJECTION INCLUDING THE COMPOSITION

IPC classification:
A61K 9/00, A61K 47/18, A61K 47/26, C07K 16/18
Applicant:
Novartis AG
Agent:
Stephan Teipel, Lederer Keller Patentanwälte Partnerschaft mbB
Agent:
Michael Stierwald, Novartis Pharma AG
Status:
EXAMINATION IN PROGRESS
EP15162722

LOW DOSE LIPOIC ACID PHARMACEUTICAL COMPOSITIONS AND METHODS

IPC classification:
A01N 37/00, A61K 31/19
Agent:
Vossius & Partner Patentanwälte Rechtsanwälte mbB
Agent:
Michael Stierwald, Novartis Pharma AG
Status:
EXAMINATION IN PROGRESS
EP13860388

FINAFLOXACIN SUSPENSION COMPOSITIONS

IPC classification:
A61K 9/00, A61K 31/5383
Applicant:
Alcon Research, Ltd
Agent:
Michael Best, Lederer Keller Patentanwälte Partnerschaft mbB
Agent:
Michael Stierwald, Novartis Pharma AG
Status:
GRANT OF PATENT INTENDED
EP14707567

TOPICAL OCULAR ANALGESIC AGENTS

IPC classification:
A61K 9/00, A61K 31/53, A61K 47/40
Applicant:
Novartis AG
Agent:
Grünecker Patent- und Rechtsanwälte PartG mbB
Agent:
Michael Stierwald, Novartis Pharma AG
Status:
EXAMINATION REQUESTED
EP15179323

CARBOXYVINYL POLYMER-CONTAINING NANOPARTICLE SUSPENSIONS

IPC classification:
A61K 9/10, A61K 9/14, A61K 31/165, A61K 47/02, A61K 47/32, A61K 47/36, A61P 27/02
Applicant:
Novartis AG
Applicant:
Alcon Research, Ltd
Agent:
Stephan Teipel, Lederer Keller Patentanwälte Partnerschaft mbB
Agent:
Michael Stierwald, Novartis Pharma AG
Status:
EXAMINATION IN PROGRESS
EP15169431

METHOD OF TREATMENT OR PROPHYLAXIS OF INFLAMMATORY PAIN

IPC classification:
A61K 31/00, A61K 31/395, A61K 38/00, A61K 38/07, A61K 38/08, A61P 25/04, A61P 29/00, C07D 217/26, C07D 241/04, C07D 401/06, C07D 409/06, C07D 471/04, G01N 33/74
Applicant:
Novartis AG
Agent:
D Young & Co LLP
Agent:
Michael Stierwald, Novartis Pharma AG
Status:
EXAMINATION REQUESTED
EP15185071

OLOPATADINE FORMULATIONS FOR TOPICAL NASAL ADMINISTRATION

IPC classification:
A61K 9/00, A61K 9/08, A61K 31/335, A61K 47/02, A61K 47/18
Applicant:
Novartis AG
Agent:
Michael Best, Lederer Keller Patentanwälte Partnerschaft mbB
Agent:
Michael Stierwald, Novartis Pharma AG
Status:
EXAMINATION REQUESTED
EP13162570

Method of treatment or prophylaxis

IPC classification:
A61K 31/517, A61K 38/08, A61P 25/02, A61P 25/06, C07D 295/215
Applicant:
Novartis AG
Agent:
Kirk James Gallagher, D Young & Co LLP
Agent:
Michael Stierwald, Novartis Pharma AG
Status:
GRANT OF PATENT INTENDED
EP13162564

Method of treatment or prophylaxis

IPC classification:
A61K 31/517, A61K 38/08, A61P 25/02, A61P 25/06
Applicant:
Novartis AG
Agent:
Kirk James Gallagher, D Young & Co LLP
Agent:
Michael Stierwald, Novartis Pharma AG
Status:
GRANT OF PATENT INTENDED
EP11740973

SALT AND SOLVATES OF A TETRAHYDROISOQUINOLINE DERIVATIVE

IPC classification:
C07D 217/26
Applicant:
Novartis AG
Agent:
Donald C. McNab, Marks & Clerk LLP
Agent:
Michael Stierwald, Novartis Pharma AG
Status:
NO OPPOSITION FILED WITHIN TIMELIMIT
EP14736523

TOPICAL AQUEOUS OPHTHALMIC COMPOSITIONS CONTAINING A 1H-INDOLE-1-CARBOXAMIDE DERIVATIVE AND USE THEREOF FOR TREATMENT OF OPHTHALMIC DISEASE

IPC classification:
A61K 9/00, A61K 9/08, A61K 31/506, A61K 31/519, A61K 47/02, A61K 47/10, A61K 47/18, A61K 47/26, A61K 47/32, A61K 47/34, A61K 47/38, A61P 27/02
Applicant:
Novartis AG
Agent:
Günter Keller, Lederer Keller Patentanwälte Partnerschaft mbB
Agent:
Michael Stierwald, Novartis Pharma AG
Status:
GRANT OF PATENT INTENDED
EP14733730

USE OF A VEGF ANTAGONIST IN TREATING CHOROIDAL NEOVASCULARISATION

IPC classification:
A61K 38/17, A61K 39/395, A61K 47/48, A61P 27/02
Applicant:
Novartis AG
Agent:
Michael Stierwald, Novartis Pharma AG
Status:
EXAMINATION REQUESTED
EP14733729

TREATMENT OF POLYPOIDAL CHOROIDAL VASCULOPATHY

IPC classification:
A61K 38/18, A61K 41/00
Applicant:
Novartis AG
Agent:
Michael Stierwald, Novartis Pharma AG
Status:
GRANT OF PATENT INTENDED
EP14733731

USE OF A VEGF ANTAGONIST IN TREATING MACULAR EDEMA

IPC classification:
A61K 38/17, A61K 39/395, A61K 47/48, A61P 27/02
Applicant:
Novartis AG
Agent:
Michael Stierwald, Novartis Pharma AG
Status:
GRANT OF PATENT INTENDED
EP14741406

USE OF A VEGF ANTAGONIST IN TREATING CHORIORETINAL NEOVASCULAR AND PERMEABILITY DISORDERS IN PAEDIATRIC PATIENTS

IPC classification:
A61K 39/395, A61P 27/02, C07K 16/22
Applicant:
Novartis AG
Agent:
Michael Stierwald, Novartis Pharma AG
Status:
GRANT OF PATENT INTENDED
EP14772237

METHOD FOR TREATING OTIC INFECTIONS AFTER TYMPANOSTOMY TUBE PLACEMENT

IPC classification:
A61K 9/00
Applicant:
Novartis AG
Agent:
Carpmaels & Ransford LLP
Agent:
Michael Stierwald, Novartis Pharma AG
Status:
GRANT OF PATENT INTENDED
EP16156221

OPHTHALMIC COMPOSITION WITH A VISCOSITY ENHANCEMENT SYSTEM HAVING TWO DIFFERENT VISCOSITY ENHANCING AGENTS

IPC classification:
A61K 9/00, A61K 9/08, A61K 47/10, A61K 47/32, A61K 47/34, A61K 47/38
Applicant:
Novartis AG
Applicant:
Alcon Research, Ltd
Agent:
Stephan Teipel, Lederer Keller Patentanwälte Partnerschaft mbB
Agent:
Michael Stierwald, Novartis Pharma AG
Status:
EXAMINATION REQUESTED
EP16158101

HIGH CONCENTRATION OLOPATADINE OPHTHALMIC COMPOSITION

IPC classification:
A61K 9/00, A61K 9/08, A61K 31/335, A61K 47/10, A61K 47/32, A61K 47/40, A61P 27/14, C08L 5/16
Applicant:
Novartis AG
Applicant:
Alcon Research, Ltd
Agent:
Stephan Teipel, Lederer Keller Patentanwälte Partnerschaft mbB
Agent:
Michael Stierwald, Novartis Pharma AG
Status:
EXAMINATION REQUESTED
EP15200360

SALT AND SOLVATES OF A TETRAHYDROISOQUINOLINE DERIVATIVE

IPC classification:
C07D 217/26
Applicant:
Novartis AG
Agent:
Michael Stierwald, Novartis Pharma AG
Status:
EXAMINATION REQUESTED
EP15758583

LIPOIC ACID CHOLINE ESTER COMPOSITIONS AND METHODS OF USE

IPC classification:
A01N 43/26
Agent:
Maiwald Patentanwalts GmbH
Agent:
Michael Stierwald, Novartis Pharma AG
Status:
EXAMINATION REQUESTED

Please Sign in to use this feature